Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis.

CONCLUSIONS: Immune cell components of the TME have prognostic value in early-stage, surgically resected NSCLC, and may reveal which patients are more likely to need additional systemic treatment, including immunotherapy. Clinical covariates need to be considered when evaluating the prognostic value of immune cells in the TME. PMID: 31903172 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31903172?dopt=Abstract

Source: Oncotarget - January 8, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research